Noradrenergic versus serotonergic antidepressants:
predictors of treatment
response
by
Schatzberg AF
Department of Psychiatry and Behavioral Sciences,
Stanford University School
of Medicine,
Calif 94303-5548, USA.
J Clin Psychiatry 1998; 59 Suppl 14:15-8
ABSTRACT
Serotonin selective reuptake inhibitors (SSRIs) have generally proven to be
as effective as tricyclic antidepressants (TCAs) in the treatment of major
depression and have an improved side effect profile. However, data suggest that
the SSRIs are not as effective as the TCAs in certain subsets of depressed
patients, indicating the importance of norepinephrine reuptake inhibition for
such patients. Evidence for the role of norepinephrine in depression comes from
early studies on excretion of catecholamines and more recent studies on receptor
function, second messenger systems, and gene modification. These data are
reviewed in this article. Data from a multicenter, randomized, controlled
clinical trial comparing desipramine, a relatively norepinephrine-selective TCA,
and the SSRI fluoxetine in moderate to marked major depression suggest a
differential response depending on the antidepressant. The 2 drugs were overall
similar in efficacy; however, in severely ill patients, there was a suggestion
that desipramine was more likely to induce remission than fluoxetine. Urinary
metabolite 3-methoxy-4-hydroxyphenylglycol levels were a better predictor of
likelihood of remission than severity of episode or drug treatment. Desipramine
and fluoxetine produced different longitudinal effects in catecholamine
excretion, indicating that the 2 agents act through different mechanisms. Given
the good therapeutic profile but relative risks associated with TCA therapy,
selective norepinephrine reuptake inhibitors, such as reboxetine, which has a
good safety profile, could be a major step forward in the treatment of
depression.
Options
Predicting response
Noradrenaline and dopamine
Reboxetine versus fluoxetine
Serotonin reuptake inhibition
Dopamine reuptake inhibition
Noradrenaline reuptake inhibition
Reboxetine and major depression
Refs
HOME
HedWeb
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative

The Good Drug Guide
The Responsible Parent's Guide
To
Healthy Mood Boosters For All The Family